|
|
|
|
|||||
|
|
|
Conference call and webcast: today, May 21, 2025, 9:00 am ET
Financial Highlights:
REHOVOT, Israel, May 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter ended March 31, 2025.
Mr. Ofer Haviv, Evogene's President and CEO, stated: "As part of our ongoing strategy to build a more capital-efficient and value-driven business model, Evogene is focusing on two key priorities: unlocking the full potential of our ChemPass-AI tech-engine in the pharmaceutical sector, and generating cash flow and strategic value from our subsidiaries. These efforts are designed to accelerate near-term monetization opportunities while reinforcing our long-term growth trajectory.
"We've made significant progress in advancing ChemPass-AI tech-engine, our proprietary AI platform for small molecule drug discovery. Over the past quarter, we sharpened its value proposition for the pharma and biotech industries, with a clear focus on addressing a core challenge—designing highly potent, novel compounds that meet complex multi-parameter requirements. An example of our unique ChemPass-AI offering is the foundation model developed in collaboration with Google Cloud, at the core of our lead-optimization activity. Trained on an unparalleled dataset of approximately 38 billion molecules, this model expands our ability to discover structurally unique and clinically relevant compounds, significantly improving the likelihood of success in preclinical and clinical stages. This positions ChemPass-AI as a differentiated and commercially attractive solution for pharma partners seeking next-generation discovery capabilities.
"In parallel, we are taking concrete steps to generate value from our subsidiaries. In April, we announced the acquisition of the majority of Lavie Bio's operations by ICL. This transaction is expected to generate value for Evogene in two ways: directly, through the sale of MicroBoost AI for Ag and indirectly, through dividends. We can also envision long-term upside for Evogene from certain existing collaboration agreements which remain in Lavie Bio and are not part of the transaction. We continue to explore similar strategic opportunities across our subsidiary portfolio, with the goal of unlocking shareholder value and supporting our broader mission through disciplined execution."
"We are confident that these strategic initiatives will drive sustainable growth and position Evogene for long-term success in the evolving life sciences landscape," Mr. Haviv concluded.
Subsidiaries Updates:
Lavie Bio Ltd. – a leading ag-biologicals company that develops microbiome-based, novel bio-stimulant and bio-pesticide products, utilizing Evogene's MicroBoost AI tech-engine.
Casterra Ag Ltd. – focuses on developing integrated solutions for large-scale castor bean farming, utilizing GeneRator AI tech-engine.
AgPlenus Ltd. – specializes in developing novel and sustainable crop protection products, utilizing Evogene's ChemPass AI tech-engine.
Biomica Ltd. – a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, utilizing Evogene's MicroBoost AI tech-engine.
Financial Highlights:
Cash Position: As of March 31, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $9.8 million, compared to approximately $15.3 million as of December 31, 2024. This cash balance does not reflect approximately $2.0 million due from Casterra's outstanding customers, the majority of which were received in the second quarter of 2025. Excluding Lavie Bio and Biomica, Evogene and its other subsidiaries used approximately $3.0 million in cash during the first quarter of 2025.
Revenue: Revenues for the first quarter of 2025 were approximately $2.4 million, a decrease from approximately $4.2 million in the same period of the previous year. This decline was primarily due to revenues recognized in 2024 from Lavie Bio's license agreement with Corteva and AgPlenus's license agreement with Bayer. In 2025, revenues were mainly driven by Casterra's increased seed sales.
R&D Expenses: Research and development expenses for the first quarter of 2025 were approximately $3.2 million, a significant decrease from approximately $4.8 million in the same period of the previous year. The decrease in expenses in 2025 was mainly due to lower research and development expenses in Biomica and Lavie Bio compared to the same period the previous year, as well as the closure of Canonic's operations during the first half of 2024.
Sales and Marketing Expenses: Sales and marketing expenses decreased to approximately $645 thousand in the first quarter of 2025 compared to approximately $992 thousand in the same period last year. The decrease was primarily driven by a reduction in Lavie Bio's sales and marketing activities this year.
General and Administrative Expenses: General and administrative expenses decreased to approximately $1.3 million in the first quarter of 2025, compared to approximately $1.7 million in the same period last year. The decrease was primarily attributable to reduced expenses related to Lavie Bio and Evogene, as well as the closure of Canonic's operations during the first half of 2024.
Other Expenses (Income): Other income of approximately $191 thousand was recorded in the first quarter of 2025 as part of the accounting treatment related to a sub-lease agreement. The decision to cease Canonic's operations in the first half of 2024 resulted in other expenses of approximately $0.5 million, primarily due to the impairment of fixed assets recorded in the first quarter of 2024.
Operating Loss: Operating loss for the first quarter of 2025 remained stable at approximately $4.1 million, similar to the operating loss reported in the first quarter of 2024.
Financing Income / Expenses: Net financing income for the first quarter of 2025 was approximately $1.1 million, compared to net financing income of approximately $241 thousand in the same period last year. The increase was primarily due to the accounting treatment of pre-funded warrants and warrants issued in Evogene's August 2024 fundraising.
Net Loss: The net loss for the first quarter of 2025 was approximately $3.0 million, compared to approximately $3.8 million in the same period last year. The $0.8 million decrease in net loss was primarily due to reduced operating expenses and increased net financing income, partially offset by decreased revenues, as noted above.
For the financial tables click here.
Conference Call & Webcast Details: Wednesday, May 21, 2025, 9:00 AM EST 4:00 PM IDT
To join the Zoom conference, please register in advance here
Webcast & Presentation link available at:
https://evogene.com/investor-relations/
About Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss the expected closing of the Lavie Bio – ICL transaction and the expected proceeds from such transaction and generation of value and long-term upside to Evogene, expected completion of Evogene's and Biomica's expense reduction plans and savings therefrom, ChemPass-AI being a differentiated and commercially attractive solution for pharma partners, Evogene's strategic initiatives, including achieving value from its subsidiaries, and their expected outcome to drive sustainable growth and position Evogene for long-term success in the evolving life sciences landscape, the timing of Casterra's trial results and Biomica's ability to raise funds which are required for Phase II of clinical study. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Evogene Investors Relations Contact:
Email: [email protected]
Tel: +972-8-9311901
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
March 31, | December 31, | |||
2025 | 2024 | |||
Unaudited | ||||
ASSETS | ||||
CURRENT ASSETS: | ||||
Cash and cash equivalents | $ 7,495 | $ 15,301 | ||
Short-term bank deposits | 2,354 | 10 | ||
Trade receivables | 2,640 | 1,091 | ||
Other receivables and prepaid expenses | 651 | 2,064 | ||
Deferred expenses related to issuance of warrants | 1,209 | 1,304 | ||
Inventories | 2,152 | 1,819 | ||
16,501 | 21,589 | |||
LONG-TERM ASSETS: | ||||
Long-term deposits and other receivables | 162 | 12 | ||
Investment in an associate | 80 | 82 | ||
Deferred expenses related to issuance of warrants | 1,505 | 1,735 | ||
Right-of-use-assets | 2,480 | 2,447 | ||
Property, plant and equipment, net | 1,621 | 1,804 | ||
Intangible assets, net | 11,955 | 12,195 | ||
17,803 | 18,275 | |||
TOTAL ASSETS | $ 34,304 | $ 39,864 | ||
LIABILITIES AND EQUITY | ||||
CURRENT LIABILITIES: | ||||
Trade payables | $592 | $ 1,228 | ||
Employees and payroll accruals | 1,622 | 1,869 | ||
Lease liabilities | 670 | 589 | ||
Liabilities in respect of government grants | 353 | 323 | ||
Deferred revenues and other advances | 209 | 360 | ||
Warrants and pre-funded warrants liability | 1,169 | 2,876 | ||
Convertible SAFE | 10,371 | 10,371 | ||
Other payables | 613 | 1,079 | ||
15,599 | 18,695 | |||
LONG-TERM LIABILITIES: | ||||
Lease liabilities | 1,922 | 1,914 | ||
Liabilities in respect of government grants | 4,302 | 4,327 | ||
Deferred revenues and other advances | 86 | 90 | ||
6,310 | 6,331 | |||
TOTAL LIABILITIES | $ 21,909 | $ 25,026 |
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
SHAREHOLDERS' EQUITY: | ||||
Ordinary shares of NIS 0. 2 par value: Authorized − 15,000,000 ordinary shares; Issued and | 372 | 363 | ||
Share premium and other capital reserves | 272,641 | 272,257 | ||
Accumulated deficit | (276,658) | (274,071) | ||
Equity attributable to equity holders of the Company | (3,645) | (1,451) | ||
Non-controlling interests | 16,040 | 16,289 | ||
TOTAL EQUITY | 12,395 | 14,838 | ||
TOTAL LIABILITIES AND EQUITY | $ 34,304 | $ 39,864 |
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS
U.S. dollars in thousands (except share and per share amounts)
Three months ended March 31, | Year ended December 31, | |||||
2025 | 2024 | 2024 | ||||
Unaudited | ||||||
Revenues | $ 2,444 | $ 4,190 | $ 8,511 | |||
Cost of revenues | 1,614 | 310 | 2,683 | |||
Gross profit | 830 | 3,880 | 5,828 | |||
Operating expenses (income): | ||||||
Research and development, net | 3,208 | 4,801 | 16,648 | |||
Sales and marketing | 645 | 992 | 3,425 | |||
General and administrative | 1,294 | 1,654 | 7,441 | |||
Other expenses (income) | (191) | 519 | 524 | |||
Total operating expenses, net | 4,956 | 7,966 | 28,038 | |||
Operating loss | (4,126) | (4,086) | (22,210) | |||
Financing income | 1,603 | 407 | 7,546 | |||
Financing expenses | (464) | (166) | (3,342) | |||
Financing income, net | 1,139 | 241 | 4,204 | |||
Share of loss of an associate | 2 | - | 39 | |||
Loss before taxes on income | (2,989) | (3,845) | (18,045) | |||
Taxes on income | - | - | 9 | |||
Loss | $ (2,989) | $ (3,845) | $ (18,054) | |||
Attributable to: | ||||||
Equity holders of the Company | (2,587) | (3,863) | (16,485) | |||
Non-controlling interests | (402) | 18 | (1,569) | |||
$ (2,989) | $ (3,845) | $ (18,054) | ||||
Basic and diluted loss per share, attributable to | $ (0.38) | $ (0.76) | $ (2.89) | |||
Weighted average number of shares used in | 6,798,173 | 5,083,116 | 5,697,245 | |||
(*) Shares and per share amounts have been retroactively adjusted to reflect the 1:10 reserve stock split | ||||||
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Three months ended March 31, | Year ended December 31, | ||||||
2025 | 2024 | 2024 | |||||
Unaudited | |||||||
Cash flows from operating activities: | |||||||
Loss | $ (2,989) | $ (3,845) | $ (18,054) | ||||
Adjustments to reconcile loss to net cash used in operating | |||||||
Adjustments to the profit or loss items: | |||||||
Depreciation and amortization of property, plant and | 339 | 426 | 1,530 | ||||
Amortization of intangible assets | 240 | 245 | 974 | ||||
Share-based compensation | 316 | 539 | 1,795 | ||||
Remeasurement of Convertible SAFE | - | (25) | 3 | ||||
Net financing income | 1 | (194) | (689) | ||||
Loss from sale of property, plant and equipment | - | 519 | 524 | ||||
Gain from deduction of right-of-use asset and subsequent | (191) | - | - | ||||
Excess of initial fair value of pre-funded warrants over | - | - | 2,684 | ||||
Amortization of deferred expenses related to issuance of | 326 | - | 471 | ||||
Remeasurement of pre-funded warrants and warrants | (1,477) | - | (6,529) | ||||
Share of loss of an associate | 2 | - | 39 | ||||
Taxes on income | - | - | 9 | ||||
(444) | 1,510 | 811 | |||||
Changes in asset and liability items: | |||||||
Increase in trade receivables | (1,549) | (182) | (734) | ||||
Decrease (increase) in other receivables and prepaid | 1,467 | (179) | 925 | ||||
Increase in inventories | (333) | (640) | (1,743) | ||||
Decrease in trade payables | (515) | (685) | (596) | ||||
Decrease in employees and payroll accruals | (247) | (105) | (668) | ||||
Increase (decrease) in other payables | (466) | (61) | 62 | ||||
Decrease in deferred revenues and other advances | (155) | (71) | (559) | ||||
(1,798) | (1,923) | (3,313) | |||||
Cash received (paid) during the year for: | |||||||
Interest received | 95 | 171 | 934 | ||||
Interest paid | (46) | (23) | (67) | ||||
Taxes paid | - | - | (11) | ||||
Net cash used in operating activities | $ (5,182) | $ (4,110) | $ (19,700) | ||||
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Three months ended March 31, | Year ended December 31, | |||||||
2025 | 2024 | 2024 | ||||||
Unaudited | ||||||||
Cash flows from investing activities: | ||||||||
Purchase of property, plant and equipment | $ (122) | $ (141) | $ (626) | |||||
Proceeds from sale of property, plant and equipment | - | 10 | 58 | |||||
Proceeds from finance sub -lease asset | 2 | - | - | |||||
Proceeds from short-term bank deposits | - | 1,210 | 27,340 | |||||
Investment in short-term bank deposits | (2,326) | (5,441) | (17,150) | |||||
Net cash provided by (used in) investing activities | (2,446) | (4,362) | 9,622 | |||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of ordinary shares, pre-funded | - | - | 5,500 | |||||
Proceeds from issuance of ordinary shares, net of issuance | - | 3 | 123 | |||||
Repayment of lease liabilities | (143) | (231) | (901) | |||||
Proceeds from government grants | 106 | - | 232 | |||||
Repayment of government grants | (122) | (139) | (298) | |||||
Net cash provided by (used in) financing activities | (159) | (367) | 4,656 | |||||
Exchange rate differences on balances of cash and cash | (19) | (18) | (49) | |||
Decrease in cash and cash equivalents | (7,806) | (8,857) | (5,471) | |||
Cash and cash equivalents at the beginning of the period | 15,301 | 20,772 | 20,772 | |||
Cash and cash equivalents at the end of the period | $ 7,495 | $ 11,915 | $ 15,301 | |||
Significant non-cash activities | ||||||
Purchase of property, plant and equipment | $ - | $ 22 | $ 120 | |||
Right-of-use asset recognized with corresponding lease | $ 207 | $ 130 | $ 2,307 | |||
Exercise of pre-funded warrants | $ 229 | $ - | $ 2,289 | |||
Derecognition of property, plant and equipment under a | $ 13 | $ - | $ - | |||
Investment in affiliated company with corresponding deferred | $ - | $ 120 | $ 120 |
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
SOURCE Evogene
| Jun-10 | |
| May-22 | |
| May-21 | |
| May-14 | |
| May-08 | |
| Apr-22 | |
| Apr-21 | |
| Mar-06 | |
| Mar-06 | |
| Feb-20 | |
| Feb-13 | |
| Nov-21 | |
| Nov-19 | |
| Nov-12 | |
| Nov-07 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
